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System-Wide Implementation of the Use of an Extended-Infusion Piperacillin/Tazobactam
Dosing Strategy: Feasibility of Utilization From a Children's Hospital Perspective
Kristen R. Nichols, Chad A. Knoderer, Elaine G. Cox, Michael B. Kays

Abstract
Background
Use of extended infusions of piperacillin/tazobactam (PT) in adult patients has been described,
but data in children are limited.
Objective
The goal of this study was to determine the feasibility of using an extended-infusion PT dosing
strategy as the standard of care in a children's hospital.
Methods
This was a prospective observational study of patients aged >30 days who received PT after
admission to a freestanding, tertiary care children's hospital. After institution of an extendedinfusion PT dosing protocol as the standard dosing option, patients receiving PT were
prospectively assessed for presence of and reasons for changes in dosing regimen.
Results
A total of 332 patients, with a median age of 5 years (interquartile range, 1.9–12 years) and
median weight of 19.9 kg (interquartile range, 11.7 – 37.6 kg) received PT (100 mg/kg based on
piperacillin component). Extended-infusion PT was used for the duration of PT therapy in 92%
(n = 304) of patients. Twenty-eight patients (8%) received a traditional infusion over 30 minutes,
with 19 of 28 being changed from extended infusion and 9 of 28 being empirically prescribed
traditional infusion PT. The most commonly encountered reason for not using extended infusions
was coadministration of vancomycin (17 of 28 [61%]) and lack of compatibility data with PT.
Dosing errors, which were voluntarily reported, were infrequent (1.8% [n = 6]). The few
observed dosing errors were likely attributable to the overall ordering process at our institution,
which requires ordering as the milligram per kilogram dose as total PT rather than based on
piperacillin component as is commonly documented in pediatric dosing references.
Conclusions
Results of this study suggest that extended-infusion PT dosing was feasible in this specific
children's hospital. Ninety-two percent of patients received our institution's preferred dosing
regimen; a small percentage of patients still needed to receive traditional infusion times.

Introduction

Increasing prevalence of antimicrobial resistance is a growing issue encountered on a daily basis
in hospitals caring for children.1, 2, 3, 4, 5 and 6 Few alternative antibacterial agents are available to
treat infections caused by multidrug resistant bacteria, primarily due to limited available
pediatric tolerability and efficacy data and, ultimately, limited published experience with using
such agents in pediatric patients. With developmental pharmacologic changes observed along the
continuum of “pediatrics,” simply extrapolating adult dosages to a pediatric patient is not always
the safest or most effective approach.7 Although detrimental effects on development have not
been documented, there are few published data to establish optimal use, dose, and duration for
alternatives to β-lactam antibacterial agents such as fluoroquinolones, aminoglycosides,
tetracycline derivatives, and colistin. However, these medications may represent the entire
antibacterial arsenal for the treatment of infections caused by resistant gram-negative bacteria in
children, thereby requiring careful risk/benefit assessments. As with adult studies, pediatric
studies have reported negative clinical outcomes associated with infections due to resistant
bacteria, including increased length of stay and mortality.2 and 8
From a pediatric care perspective, it is critical to optimize the dosing of the currently available
antibacterial agents based on drug-specific pharmacokinetic and pharmacodynamic parameters,
thus increasing the probability that positive patient outcomes are maximized while minimizing
the selective pressure for emergence of antibiotic resistance.9 and 10 In general, β-lactam
antibiotics and antibiotic combinations, such as piperacillin-tazobactam (PT), exhibit timedependent bactericidal activity and, with the exception of carbapenems, minimal postantibiotic
effects.9 As a result, their pharmacodynamics are optimized by achieving a requisite length of
time for which the free antibiotic concentrations remain above the MIC (fT > MIC) for the
infecting organism. There is no apparent difference between adults and children with respect to
these pharmacodynamic properties. Thus, any potential or proven benefits of optimizing
pharmacodynamic exposures should apply to children as well as to adults.
Optimization of the PT bactericidal exposures can be achieved by increasing the dose while
keeping the dosing interval the same, administering the same dose at more frequent intervals,
administering the dose as a continuous infusion, or extending the duration of intermittent
infusions.11 Although there are certain pharmacokinetic differences observed between children
and adults, the pharmacokinetic profiles of piperacillin and tazobactam, specifically t½ values,
reach adult values by 2 years of age.7, 12 and 13 Doubling the dose of PT increases the fT > MIC by
only ∼1 t½ of the medication. 14 Administering the medication at more frequent intervals would
require 4-hour dosing intervals compared with 6-hour intervals, which may create a significant
burden on nursing staff depending on the institution.
A potential solution is to use continuous or extended-infusion dosing strategies in children.
Extended-infusion PT (EIPT) has been well described in adult patients, and many adult studies
have evaluated the attainment of the target % fT > MIC by using Monte Carlo simulation. 11, 15, 16,
17, 18, 19, 20, 21, 22, 23, 24 and 25
Lorente et al 26 reported superior clinical cure in ventilator-associated
pneumonia with continuous versus intermittent PT infusions. Although not definitive with
respect to extended-infusion dosing, the findings provide support for improved clinical outcomes
with optimizing dosing strategies of our existing antibacterial agents to maximize fT > MIC. A
common concern when considering continuous or extended-infusion regimens in children is that
compatibility issues could arise due to the child's limited number of intravenous (IV) access

sites, although this is less problematic with extended-infusion regimens compared with
continuous infusion regimens.
After conducting a PubMed search using combinations of the terms piperacillin/tazobactam,
beta-lactam, pharmacodynamics, pharmacokinetics, prolonged infusion, and extended infusion,
it was determined that description of EIPT in a pediatric population is limited to 1 study which
explored the probability of pharmacodynamic target attainment using Monte Carlo simulations
and no direct patient intervention. 27 By simulating an extended or continuous infusion of βlactam antibacterial agents, the authors reported an increased probability of target attainment for
Pseudomonas aeruginosa isolates with elevated MICs. Although this study is useful for
estimating effects of prolonged infusion, an ability to administer medications as prolonged or
continuous infusions in actual patients was not addressed. Having implemented an EIPT dosing
protocol in our institution, the objective of the current study was to describe implementation of
an EIPT dosing strategy as the standard of care in a children's hospital.

Methods
Study Population and Setting
This was a descriptive study performed after the implementation of EIPT as the standard of care
in a freestanding, tertiary care children's hospital. At our institution, PT is a common
combination antibacterial agent for suspected or confirmed gram-negative bacterial infections.
Traditionally, it has been dosed at 75 mg/kg/dose (based on piperacillin component) every 6 to 8
hours via a 30-minute infusion. In April 2011, our health system's Pharmacy and Therapeutics
Committee, with the support of the Pediatric Antimicrobial Stewardship Program (PAS),
approved a system-wide change to 4-hour infusions of PT. Based on our institutional
susceptibility data, it was estimated that the target fT > MIC would be achieved in 15% to 30%
more isolates of P aeruginosa with EIPT. This was a system-wide change in dosing strategy for
both pediatric and adult patients in each of the system hospitals, with PAS support. After
hospital-wide education to pharmacists, physicians, and nurses provided by PAS members and
the nursing education team, our hospital changed its traditional practice to dosing PT at 100
mg/kg/dose (based on piperacillin component) every 8 hours via 4-hour infusion. This regimen
became the standard PT dose and administration method for all patients in the hospital with the
exception of neonates or patients encountered in the neonatal intensive care unit, operating areas,
outpatient infusion clinics, or emergency department. Although published pediatric
pharmacodynamic simulations used a 3-hour infusion time, our hospital is part of a larger health
care system consisting of both adult and adult/pediatric mixed hospitals, and a 4-hour infusion
time was chosen for system standardization as well as smart pump programming. 27
Prescribers within our institution are required to order IV antibacterial agents via a preprinted
order form. Implementation of the new dosing strategy included changing the dosing on the
required preprinted form to the extended-infusion regimen and removing the traditional 30minute infusion. Prescribers were allowed to order PT via a 30-minute infusion if they thought
that dosing was medically necessary, but prescribers had to write the entire medication order,
including dose, on a blank line on the order form. Both the 4-hour and 30-minute infusions were
administered by using an Alaris Pump (CareFusion Corporation, San Diego, California).

Patients were included if they received at least 1 dose of IV PT within our institution from April
5, 2011, to July 5, 2011, which was a period after EIPT implementation. Patients were identified
daily by using the pharmacy computer system and by reviewing inpatient antibacterial orders.
Exclusion criteria were admission to the neonatal intensive care unit, age <30 days, and PT
administration in the operating areas, outpatient infusion clinics, or emergency department.
These exclusions were the same as are listed in the hospital's EIPT dosing protocol. The
institutional review board at Indiana University–Purdue University at Indianapolis approved the
study with waiver of consent.
Data were collected prospectively from the patient's medical record as a quality assurance project
relating to the relationship of PAS and the Quality Council at our institution. Subsequently,
exempt institutional review board approval was granted on the decision to share our experience.
Patient demographic characteristics were collected in addition to PT dosing information (dose,
frequency, infusion time, and duration of therapy), concomitantly ordered medications, number
of available IV lumens, and indication for PT. Medications and IV access points were
documented once at the time of data collection, although these parameters may have been
frequently changing. Therapy was defined as targeted if a specific infection was targeted (cystic
fibrosis exacerbation, positive culture, perforated appendicitis, and hospital-acquired pneumonia)
or empiric if PT was administered for febrile neutropenia or in the process of ruling out an
infection. Reasons for not using the 4-hour infusion time were obtained as documented in the
medical record; pharmacists or physicians were queried for this information if it was not found in
the medical record. At the end of the study period, the institutional IV placement team was
questioned regarding an observed change in peripheral IV placement. The primary outcome in
this study was the feasibility of EIPT, determined by the percentage of PT courses that were
changed to the traditional 30-minute infusion. A low percentage (<20%) of use of traditional
infusions would confirm feasibility of this dosing strategy.

Statistical Analysis
Descriptive statistics were used for patient demographic characteristics, the percentage of PT
courses administered via extended infusion, and the percentage of dosing errors. Statistical
analysis was conducted by using Microsoft Excel 2007 (Microsoft Corporation, Redmond,
Washington).

Results
A total of 332 patients met study inclusion. Median patient age was 5 years (interquartile range,
1.9–12 years), and median weight was 19.9 kg (interquartile range, 11.7–37.6 kg). Age
distribution is described in Table I. The pediatric critical care, hematology/oncology, general
surgery, and pulmonary services were responsible for prescribing 65.1% (n = 216) of PT courses.
Approximately 45% of patients received PT as empiric therapy while awaiting culture results
(“rule outs”) or for febrile neutropenia (Table II). The mean duration of PT therapy was 4.5
(4.2) days, with 51.2% (n = 170) of courses lasting <72 hours. Sixty-four (19.3%) courses of PT
continued for >7 days. Courses of duration >72 hours but <7 days likely represent antibiotic deescalation based on culture and susceptibility results or diagnostic indecision. A total of 174

(52.4%) patients had only 1 IV access point at time of PT initiation, and 107 (32.3%) had only 2
IV access points; 149 (44.9%) patients had only peripheral access.
Table I.
Demographic characteristics (N = 332).
Male
50.60%
Median age (IQR), y
5 (1.9-12)
Age, no. (%)
<1 y
55 (16.6)
1-5y
118 (35.5)
6-11 y
67 (20.2)
12-17 y
58 (17.5)
≥18 y
34 (10.2)
Prescribing pediatric medical service, no. (%)
Burn
1 (0.3)
Cardiology/cardiovascular surgery
23 (6.9)
Critical care
67 (20.2)
Developmental
17 (5.1)
Gastroenterology
10 (3.0)
General surgery
39 (11.7)
Genitourinary
11 (3.3)
Hematology/oncology
75 (22.6)
Hospitalist
6 (1.8)
Infectious diseases
3 (0.9)
Nephrology
4 (1.2)
Neurosurgery
4 (1.2)
Orthopedics
4 (1.2)
Plastic surgery
9 (2.7)
Pulmonary
35 (10.5)
Transplant
13 (3.9)
Trauma
3 (0.9)
Stem cell transplant
8 (2.4)

Table II.
Indications for piperacillin/tazobactam prescription (N = 332).
Indication
No. (%) of Patients
Abdominal infection
32 (9.6)
Community-acquired pneumonia
20 (6.0)
Cystic fibrosis
18 (5.4)
Febrile neutropenia
58 (17.5)
Hospital-/health care-/ventilator-associated pneumonia
20 (6.0)
Directed therapy (blood or urine culture)
25 (7.5)
Rule-out infection
92 (27.7)
Tracheitis
13 (3.9)
Urinary tract infection (empiric)
7 (2.1)
Other
47 (14.2)

Twenty-eight (8.5%) of the 332 study patients who qualified for EIPT according to hospital
protocol were given traditional dosing and infusion times. Nineteen of those patients (5.7% of all
patients) were originally prescribed EIPT and were subsequently changed to traditional dosing
during therapy. Documented reasons for using a 30-minute infusion are shown in Table III.
Table III.
Documented reasons for 30-minute piperacillin-tazobactam infusion (n = 28).
Reason
No. (%) of Patients
Incompatibility with vancomycin coadministration
17 (60.7%)
Incompatibility with other IV medications
5 (17.9%)
Concern for limited IV access
2 (7.1%)
Prescriber confusion
2 (7.1%)
Dosing adjustment in acute kidney injury
1 (3.6%)
Organ procurement protocol
1 (3.6%)

Dosing errors occurred in a low percentage of patients who received PT (n = 6 [1.8%]). Five
patients were given doses lower than intended for EIPT. Two of these patients were prescribed
doses more similar to the traditional dosing (75 mg/kg every 6 hours). Three errors occurred
when patients received 90 mg/kg instead of 100 mg/kg as an extended infusion. In 1 case, a
prescriber ordered standard traditional dosing regimen, and that dose was lower than typically
used at our institution (65 mg/kg every 6 hours). Four nondosing medication errors were
reported. Precipitation occurred in 1 case when vancomycin was administered shortly after PT,
although the catheter was flushed with 20 mL of D5 ½NS with 10 mEq of KCl per liter (the
patient's maintenance fluid) after PT administration and before vancomycin administration.
Doses were infused over an incorrect time period twice; in 1 case, a 4-hour infusion was given
over 30 minutes and in the other case, a 30-minute infusion was given over 4 hours. The final
error occurred when an EIPT milligram dose was changed, but the order was entered to be
administered over and was given over 30 minutes rather than 4 hours. In cases of incorrect
infusion time, no patient experienced an adverse effect.

Discussion
One advantage of the extended-infusion dosing strategy is the improvement in the probability of
target attainment for microorganisms with higher MICs.27 Critics may argue that the number of
organisms with elevated MICs is lower in the pediatric population compared with the adult
population. Although it may be true that children are less likely to be infected with resistant
organisms compared with adults, higher MICs are certainly observed for organisms infecting
children.3, 6 and 27 Furthermore, optimizing dosing on the basis of pharmacodynamic parameters
may delay development of further resistance in this population, suggesting that such strategies
may be particularly effective when introduced before observation of elevated MICs.10
Another potential advantage is the economic benefit of the extended infusion strategy. In adults,
lower daily doses administered by using extended infusion achieve comparable
pharmacodynamic exposures to higher daily dosing regimens administered by intermittent
infusion.16 The omission of 1 daily dose can lead to cost savings although this is of uncertain
benefit in children, in whom the medication cost per dose is lower than in adults. However,
preparation and administration of 3 doses daily versus 4 doses (the resulting difference with
EIPT compared with traditional dosing in our institution), are associated with a decrease in
pharmacy preparation and nurse administration time costs. These costs are more difficult to
quantify than medication acquisition costs, but they are equally important. In addition, reducing
the daily number of IV line accesses may be a beneficial infection control consideration. By
limiting possible complications such as catheter-associated bloodstream infections and
associated effects on length of stay, by potentially decreasing infections with multidrug-resistant
organisms, and by optimizing outcomes, cost benefits may be substantial with this dosing
strategy.
Extended-infusion PT regimens were successfully implemented as the standard of care at our
freestanding children's hospital. Ninety-two percent of patients received extended infusion
dosing of PT. Only 8.4% of PT courses that could have been dosed by extended infusion were
dosed using the traditional 30-minute infusion. Of the courses administered over 30 minutes,
86% (24 of 28) were due to incompatibility issues or practitioner concerns.
A preprinted order form is required for ordering IV antibiotics at our institution. When the
dosing on the order form was changed to reflect EIPT (every 8-hour dosing administered over 4
hours), there were concerns raised that prescribers desiring an every 6-hour dosing regimen
would be more likely to choose a dose that was inappropriate. Since implementation of EIPT, the
incidence of dosing errors has been low. However, there are no “baseline” data with which to
compare this, and errors are voluntarily reported. The few observed dosing errors were likely
attributable to the overall ordering process at our institution, which requires ordering as the
milligram per kilogram dose as total PT rather than based on piperacillin component as is
commonly documented in pediatric dosing references. We suspect that the dosing errors were
more likely due to the overall ordering process than to a change in dosing protocol.
A fewer number of IV access points in combination with a sometimes large number of necessary
IV medications, with or without compatibility information, may be more of a challenge in a
small child compared with a larger adult. Limited IV access resulting in compatibility concerns

was the indication for reversion to the traditional dosing in 86% of occurrences, but the overall
incidence of reversion to traditional dosing from EIPT due to this reason was 7%.
Another barrier suggested before EIPT implementation was that, to comply with the dosing
strategy, there would be an increased placement of IV catheters in the pediatric patients. Indeed,
addition of more IV access sites to accommodate this dosing strategy is a concern given the
increased risk of infection of new IV access sites, which is why this practice was discouraged at
our institution. Although prescribers were instructed to change dosing instead of adding
additional IV access, it is possible that IV access did increase. Unfortunately, this study did not
include comparing patients receiving extended infusion with patients receiving traditional
infusion. However, the “IV team” at the institution, which is responsible for obtaining peripheral
IV access in patients with difficult-to-obtain IV access, observed no increased requests for
peripheral IV insertion after implementation of EIPT. It was also shown that central access was
not necessary for use of this dosing regimen, as 45% of patients had only peripheral access at the
time of antibiotic initiation.
The largest observed barrier to administration of EIPT was the lack of medication compatibility
information, especially with vancomycin. Compatibility data for the concentrations of PT and
vancomycin used at our institution (112.5 mg/mL of PT and 10 mg/mL of vancomycin) are not
available, and compatibility for other concentrations is reported to be variable.28
There are limitations to the current study. It may be difficult to generalize our findings and
experience to other hospitals or units providing medical care to children because our institution is
a tertiary care pediatric hospital with an overall institutional support structure, in both personnel
and technological resources, for this type of dosing change. Administration issues and
medication variances may have been present and either escaped identification or documentation
during the implementation. However, it is unlikely that a large number of unidentified errors or
problems occurred without drawing the attention of the prescribers or the nursing staff who were
highly invested in the dosing change. Our study period immediately followed EIPT
implementation, and it is not evident if our immediate findings will be continued. However, we
have no evidence to suggest that our success will not be sustainable.

Conclusions
Results of this study suggest that extended-infusion PT dosing was feasible in this specific
children's hospital. A high percentage of patients (92%) received our institution's preferred
dosing regimen; a small percentage of patients still needed to receive traditional infusion times.
Additional studies are warranted to determine the impact of this new dosing regimen on clinical
outcomes and prevalence of bacterial resistance.
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